310 results on '"Gradishar W"'
Search Results
52. BRCA+ test result impact and timing on surgical treatment decisions for patients with breast cancer.
53. Oncology Medical Home to address challenges in breast cancer care delivery.
54. Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC).
55. Barriers to implementing primary HER2 FISH testing.
56. The impact of BRCA testing on surgical treatment decisions for patients with breast cancer
57. A regional subgroup analysis of a multinational, double-blind, randomized, placebo-controlled, phase IIb study evaluating sorafenib (SOR) with paclitaxel (PAC) in patients (pts) with advanced breast cancer (BC).
58. Care delivery barriers to personalized medicine in breast cancer.
59. Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC).
60. Hip fractures as a complication of cancer care in perimenopausal women with breast cancer.
61. Timing of genetic testing relative to breast cancer surgery.
62. Pilot Neoadjuvant Trial with Combination of Lapatinib and Nab-Paclitaxel in HER2+ Breast Cancer.
63. A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).
64. Dasatinib Plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy Data from Phase 1 Study CA180-004.
65. A Phase I Trial of a Pegylated Liposomal Anthracycline (Doxil TM) and Lapatinib Combination in the Treatment of Metastatic Breast Cancer: Dose-Escalation Results of an Anthracycline and Lapatinib Combination Trial.
66. New Molecular Classifications of Breast Cancer
67. Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): Phase I study CA180004
68. Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program
69. Nab-paclitaxel weekly or q3w compared to docetaxel q3w as first-line therapy in patients with metastatic breast cancer: An economic analysis of a prospective randomized trial
70. 0065 Predictive factors for response to fulvestrant - the impact of prior endocrine response on treatment outcome
71. A phase I study of the oral platinum agent satraplatin (S) in with capecitabine (C) in patients (pts) with advanced solid malignancies
72. Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC)
73. Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
74. HER2 and SPARC status in tumors may play an important role in the relative effectiveness of nanoparticle albumin-bound (nab(r)) paclitaxel versus polysorbate-based docetaxel
75. Retrospective analysis of patients with poor prognostic factors and metastatic breast cancer in a phase III study comparing nab-paclitaxel to solvent-based paclitaxel
76. Overall survival analysis of a randomized phase III trial comparing nab-paclitaxel with solvent-based paclitaxel in patients with metastatic breast cancer previously treated with anthracycline
77. Randomized comparisons of weekly versus every-3-week nab-paclitaxelin patients with metastatic breast cancer
78. Comparison of weekly and every-3-week nab-paclitaxel in elderly patients with metastatic breast cancer
79. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
80. A phase II trial of capecitabine (C) in combination with the farnesyltransferase (FT) inhibitor (FTI), tipifarnib (T), in patients (pt) with metastatic breast cancer (MBC): ECOG trial 1103
81. A phase I trial of pegylated liposomal anthracycline and lapatinib (L) combination in the treatment of metastatic breast cancer (MBC): First evaluation of an anthracycline and lapatinib combination in the treatment of MBC
82. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer
83. Increased HER2 expression in women with recurrent ER positive breast cancer
84. Study supports weekly nab-paclitaxel for MBC
85. Phase II study of gemcitabine (Gem) + docetaxel (D) in combination with trastuzumab (T) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC)
86. Capecitabine-induced multifocal leukoencephalopathy: A report of five cases
87. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG
88. A case study from the Lynn Sage Comprehensive Cancer Center. Primary sarcoma of the breast: a diagnostic dilemma
89. A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC)
90. Cost-effectiveness of nanoparticle albumin-bound (nab) paclitaxel (ABX) vs Cremophor-based paclitaxel (CP) in the treatment of metastatic breast cancer (MBC)
91. 463 A multicenter phase II study of capecitabine plus paclitaxel in metastatic breast cancer: Survival update
92. LBA8 - A Phase III Randomized, Double-Blind, Trial Comparing Sorafenib Plus Capecitabine Versus Placebo Plus Capecitabine in the Treatment of Locally Advanced or Metastatic Her2-Negative Breast Cancer (Resilience)
93. Clinical potential of new antiestrogens.
94. The Impact on Survival by Adjuvant Chemotherapy and Radiation Therapy in Stage II Non-Small-Cell Lung Cancer
95. Taxanes for the Treatment of Metastatic Breast Cancer.
96. Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: The University of Chicago experience
97. Traditional and novel taxanes for the treatment of breast cancer: pitfalls, progress, and potentional: proceedings of a satellite symposium held at the European Breast Cancer Conference in April 2008.
98. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
99. Clinical review. Recent developments: breast cancer.
100. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.